Lead: States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018–24
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Lead: States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018–24
-
Narrado por:
-
De:
States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018–24
Health Affairs
Multiple federal policy changes since 2018 intended to increase buprenorphine prescribing in response to a persistent treatment gap for opioid use disorder (OUD) in the US. Anticipated national increases did not occur, but highly variable state-level trends provide important insights. This study used IQVIA data to examine all-payer and per payer prescribing across states during the period 2018–24. Researchers found that highly disparate state-level changes suggest that federal policy impacts were mediated by state-specific factors. Medicaid’s key role in driving overall prescribing highlights the public health urgency of maintaining expansions and sustaining enrollment for the single adult population.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM